Agenix Licenses Tyrian Dx Technology to Develop Microarray Device | GenomeWeb

NEW YORK (GenomeWeb News) – Australian diagnostics and biopharmaceutical firm Agenix announced today it is licensing a rapid point-of-care diagnostic technology from Tyrian Diagnostics for development of a microarray device.

Agenix will use Tyrian's DiagnosticIQ platform for human applications. Bayer CropScience currently licenses the technology for agricultural applications.

Agenix is providing Tyrian A$500,000 (US$517,000) in shares of its stock to be paid in installments through June 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.